div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: coreacuk · 2017 3 23 · nant tumor in Korea comprising 307% of all malignancy during period of study Among malignant lymphomas non-Hodgkins lymphoma accounted for 82% and src=https:reader033fdocumentsinreader033viewer202206091060a46e31e4d2b25c6d74504chtml5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: coreacuk · 2017 3 23 · nant tumor in Korea comprising 307% of all malignancy during period of study Among malignant lymphomas non-Hodgkins lymphoma accounted for 82% and src=https:reader033fdocumentsinreader033viewer202206091060a46e31e4d2b25c6d74504chtml5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: coreacuk · 2017 3 23 · nant tumor in Korea comprising 307% of all malignancy during period of study Among malignant lymphomas non-Hodgkins lymphoma accounted for 82% and src=https:reader033fdocumentsinreader033viewer202206091060a46e31e4d2b25c6d74504chtml5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: coreacuk · 2017 3 23 · nant tumor in Korea comprising 307% of all malignancy during period of study Among malignant lymphomas non-Hodgkins lymphoma accounted for 82% and src=https:reader033fdocumentsinreader033viewer202206091060a46e31e4d2b25c6d74504chtml5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: coreacuk · 2017 3 23 · nant tumor in Korea comprising 307% of all malignancy during period of study Among malignant lymphomas non-Hodgkins lymphoma accounted for 82% and...